Mural Oncology to Host First Virtual Investor Day on September 26, 2024
Mural Oncology plc - Ordinary Shares (MURA)
Company Research
Source: GlobeNewswire
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the potential of new cytokine-based immunotherapies Mural remains on track to deliver key data readouts in potentially registrational trials of nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma in 1H 2025 WALTHAM, Mass. and DUBLIN, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that it will host a virtual Investor Day on Thursday, September 26, 2024, beginning at 10 a.m. ET. Mural leadership, including Caroline Loew, Ph.D., CEO, and Vicki Goodman, MD, Chief Medical Officer, will provide new clinical insight into the trial design and assumptions of the com
Show less
Read more
Impact Snapshot
Event Time:
MURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MURA alerts
High impacting Mural Oncology plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MURA
News
- Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of CancerGlobeNewswire
- Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline ProgressGlobeNewswire
- Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Mural Oncology to Participate in Two Upcoming Investor ConferencesGlobeNewswire
- Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewswire
MURA
Sec Filings
- 11/20/24 - Form EFFECT
- 11/14/24 - Form SC
- 11/14/24 - Form SCHEDULE
- MURA's page on the SEC website